	US 12,077,826 B2
	Lipid-modified oligonucleotides and methods of using the same
Zev J. Gartner, San Francisco, CA (US); David Patterson, San Francisco, CA (US); Eric D. Chow, San Francisco, CA (US); Robert Weber, San Francisco, CA (US); and Christopher McGinnis, San Francisco, CA (US)
Assigned to The Regents of The University of California
Appl. No. 17/258,420
Filed by The Regents of The University of California, Oakland, CA (US)
PCT Filed Jul. 8, 2019, PCT No. PCT/US2019/040898 § 371(c)(1), (2) Date Jan. 6, 2021, PCT Pub. No. WO2020/010366, PCT Pub. Date Jan. 9, 2020.
Claims priority of provisional application 62/694,970, filed on Jul. 6, 2018.
Claims priority of provisional application 62/847,916, filed on May 14, 2019.
Prior Publication US 2021/0388447 A1, Dec. 16, 2021
Int. Cl. C12Q 1/6886 (2018.01); C12Q 1/6806 (2018.01)

CPC C12Q 1/6886 (2013.01) [C12Q 1/6806 (2013.01); C12Q 2600/158 (2013.01)]

18 Claims

1. A composition comprising:

(a) a first lipid-conjugated DNA oligonucleotide comprising a first lipid moiety, a first hybridization region, and a first primer region; and

(b) a second DNA oligonucleotide comprising a second primer region, a barcode region, and a capture sequence, wherein the second primer region is the reverse complement of the first primer region.